‘After we administered the peptide, we noticed a marked improvement in depression-related behaviors. The improvement seen in the peptide group was equal to the improvement on traditional anti-depressant medication’. This peptide is an entirely new approach to treating depression, which has relied on medications that primarily block serotonin or norepinephrine transporters previously. These conventional antidepressant medications don’t work for all patients, and may cause various unwanted effects. ‘We are hopeful our research will result in new choices for treatment that may have reduced side effects for patients with depressive disorder,’ Dr Liu stated..Allen Distinguished Professor in Orthopaedic Procedure, along with MU experts Bridget Garner, Aaron Stoker, Keiichi Kuroki, Cristi Make, and Prakash Jayabalan, are suffering from a test using particular biomarkers that may accurately determine if an individual is developing arthritis and also predict the potential intensity of the condition. The test could be operate off of an individual drop of liquid from a patient’s joint, which is acquired with a little needle equivalent to drawing bloodstream. Related StoriesNew era of RNAscope items for RNA-biomarker evaluation in FFPE cells releasedAbbVie plans to progress ABT-494 to Stage 3 research in rheumatoid arthritisArthritis sufferers to be better contributors to medical guideline advancement’With this biomarker check, we are able to study the degrees of specific proteins that people now know are connected with osteoarthritis,’ Cook said.